Mitoconix Bio is pioneering a novel strategy
to improve mitochondrial health

Develops disease-modifying therapeutics for neurodegenerative diseases

Mitoconix’ lead drug is a first-in-class inhibitor of pathological mitochondrial fragmentation with demonstrated in vivo efficacy in animal models of Huntington’s (HD), Parkinson’s (PD) and Alzheimer’s (AD) diseases and beneficial activity in patient-derived cells from these diseases.


Mitoconix Bio is an emerging biopharmaceutical company developing disease modifying therapies addressing unmet medical need by improving mitochondrial health.

Established in August 2016 at the FutuRx incubator, Mitoconix Bio’s lead program is based on the breakthrough scientific discoveries of its founder Daria Mochly-Rosen at Stanford University. The Stanford team has identified the molecular-based pathological interactions leading to excess mitochondrial fragmentation and identified pharmacological inhibitors of excess fission. Mitoconix exclusively licensed the technology from Stanford University.


A Disease-Modifying Therapeutic for Huntington’s Disease

A selective peptide inhibitor of pathological mitochondrial fragmentation (fission) and dysfunction

Maintains neuronal health through improved mitochondrial functions, ATP production and reduced oxidative stress in culture models of HD

Does not affect normal mitochondrial fission or fusion


Improves cell viability and mitochondrial health in HD and PD patient-derived neuronal cells

Demonstrates in vivo efficacy (improves motor and cognitive function, delays progression) in mouse HD, PD and AD models

Reduces level of Htt protein aggregates and neuronal loss (causes of the pathology) in a mouse HD model

Benefits of treatment associated with a decline in peripheral biomarkers.

Reduces neuroinflammation (microglia activation and inflammatory cytokine elevation)

Learn more about Mitoconix Bio